tolazamide (Rx)

Type 2 Diabetes

100-250 mg PO qDay or q12hr

Increase dose by 100-250 mg/day at weekly intervals to response; not to exceed 1 g/day

Fasting blood sugar <200 mg/dL

• 100 mg/day PO

Fasting blood sugar >200 mg/dL

• 250 mg/day PO

Malnurished, underweight, not eating properly, or elderly

• 100 mg/day PO

Safety and efficacy not established

Type 2 diabetes

100-250 mg PO qDay or q12hr

Increase dose by 100-250 mg/day at weekly intervals to response; not to exceed 1 g/day

Fasting blood sugar <200 mg/dL

- 100 mg/day PO

Fasting blood sugar >200 mg/dL

- 250 mg/day PO

Malnurished, underweight, not eating properly, or elderly

- 100 mg/day PO

Contraindicated (0)

Serious - Use Alternative (5)

• aminolevulinic acid oral

  aminolevulinic acid oral, tolazamide. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid administering other phototoxic drugs with aminolevulinic acid oral for 24 hr during perioperative period.

• aminolevulinic acid topical

  tolazamide increases toxicity of aminolevulinic acid topical by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration of photosensitizing drugs may enhance the phototoxic reaction to photodynamic therapy with aminolevulinic acid.

• ethanol

  ethanol, tolazamide. Other (see comment). Contraindicated. Comment: Excessive EtOH consumption may alter glycemic control. Some sulfonylureas may produce a disulfiram like rxn.

• lumacaftor/ivacaftor

  lumacaftor/ivacaftor will decrease the level or effect of tolazamide by affecting hepatic enzyme CYP2C9/10 metabolism. Avoid or Use Alternate Drug. Sulfonylureas are CYP2C9 substrates. Lumacaftor/ivacaftor has the potential to induce CYP2C9.

• methyl aminolevulinate

  tolazamide, methyl aminolevulinate. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Each drug may increase the photosensitizing effect of the other.

Monitor Closely (137)

• aceclofenac

  aceclofenac increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• acemetacin

  acemetacin increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• albiglutide

  albiglutide, tolazamide. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Serious hypoglycemia may occur when insulin secretagogues and GLP-1 agonists are concurrently administered. Consider lowering the dose of insulin secretagogue to reduce the risk of hypoglycemia. .

• alogliptin

  alogliptin, tolazamide. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of alogliptin with insulin and/or insulin secretagogues (eg, sulfonylureas, meglitinide derivatives) may increase risk for hypoglycemia; may require lower dose of insulin or insulin secretagogue .

• aripiprazole

  aripiprazole, tolazamide. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

• asenapine

  asenapine, tolazamide. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

• aspirin

  aspirin increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• aspirin rectal

  aspirin rectal increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• aspirin/citric acid/sodium bicarbonate

  aspirin/citric acid/sodium bicarbonate increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• atazanavir

  atazanavir decreases effects of tolazamide by Other (see comment). Use Caution/Monitor. Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .

• benazepril

  benazepril increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor.

• bexarotene

  bexarotene increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor. Based on the mechanism of action, bexarotene capsules may increase the action of insulin enhancing agents, resulting in hypoglycemia. Hypoglycemia has not been associated with bexarotene monotherapy.

• bitter melon

  bitter melon increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypoglycemia.

• canagliflozin

  tolazamide, canagliflozin. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with canagliflozin.

• captopril

  captopril increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor.

• celecoxib

  celecoxib increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• choline magnesium trisalicylate

  choline magnesium trisalicylate increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• cinnamon

  cinnamon increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor. Potential for hypoglycemia.

• ciprofibrate

  ciprofibrate increases effects of tolazamide by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.

• ciprofloxacin

  ciprofloxacin increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor. Hyper and hypoglycemia have been reported in patients treated concomitantly with quinolones and antidiabetic agents. Careful monitoring of blood glucose is recommended.

• clarithromycin

  clarithromycin increases levels of tolazamide by plasma protein binding competition. Use Caution/Monitor. Risk of hypoglycemia.

• clotrimazole

  clotrimazole increases levels of tolazamide by decreasing metabolism. Use Caution/Monitor.

• clozapine

  clozapine, tolazamide. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

• cyclosporine

  tolazamide, cyclosporine. unknown mechanism. Use Caution/Monitor. Cyclosporine may decrease the effects of sulfonylureas. Sulfonylureas may increase the effects of cyclosporine.

• dapagliflozin

  tolazamide, dapagliflozin. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with dapagliflozin.

• darunavir

  darunavir, tolazamide. Other (see comment). Use Caution/Monitor. Comment: Darunavir may increase or decrease levels of tolazamide. Use alternatives if available. Reports of hyperglycemia due to insulin resistance with protease inhibitors. .

• diclofenac

  diclofenac increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• diflunisal

  diflunisal increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• disopyramide

  disopyramide increases effects of tolazamide by unspecified interaction mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• dulaglutide

  dulaglutide, tolazamide. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• empagliflozin

  empagliflozin, tolazamide. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with SGLT2 inhibitors.

• enalapril

  enalapril increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor.

• ertugliflozin

  ertugliflozin, tolazamide. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with ertugliflozin.

• etodolac

  etodolac increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• exenatide injectable solution

  exenatide injectable solution, tolazamide. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of hypoglycemia when exenatide is used in combination with agents that induce hypoglycemia. Consider lowering dose of sulfonylureas to reduce risk of hypoglycemia. .

• exenatide injectable suspension

  exenatide injectable suspension, tolazamide. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of hypoglycemia when exenatide is used in combination with agents that induce hypoglycemia. Consider lowering dose of sulfonylureas to reduce risk of hypoglycemia.

• fenofibrate

  fenofibrate increases effects of tolazamide by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.

• fenofibrate micronized

  fenofibrate micronized increases effects of tolazamide by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.

• fenofibric acid

  fenofibric acid increases effects of tolazamide by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.

• fenoprofen

  fenoprofen increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• fleroxacin

  fleroxacin increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.

• fluconazole

  fluconazole increases levels of tolazamide by decreasing metabolism. Use Caution/Monitor.

• fluoxetine

  fluoxetine increases effects of tolazamide by unspecified interaction mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• flurbiprofen

  flurbiprofen increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• fosamprenavir

  fosamprenavir, tolazamide. Other (see comment). Use Caution/Monitor. Comment: Fosamprenavir may increase or decrease levels of tolazamide. Use alternatives if available. Reports of hyperglycemia due to insulin resistance with protease inhibitors. .

• fosinopril

  fosinopril increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor.

• gemfibrozil

  gemfibrozil increases effects of tolazamide by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.

• gemifloxacin

  gemifloxacin increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.

• ibuprofen

  ibuprofen increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• ibuprofen IV

  ibuprofen IV increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• iloperidone

  iloperidone, tolazamide. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

• imidapril

  imidapril increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor.

• indomethacin

  indomethacin increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• insulin aspart

  tolazamide, insulin aspart. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• insulin aspart protamine/insulin aspart

  tolazamide, insulin aspart protamine/insulin aspart. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• insulin degludec

  tolazamide, insulin degludec. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• insulin degludec/insulin aspart

  tolazamide, insulin degludec/insulin aspart. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• insulin detemir

  tolazamide, insulin detemir. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• insulin glargine

  tolazamide, insulin glargine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• insulin glulisine

  tolazamide, insulin glulisine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• insulin inhaled

  tolazamide, insulin inhaled. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• insulin isophane human/insulin regular human

  tolazamide, insulin isophane human/insulin regular human. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• insulin lispro

  tolazamide, insulin lispro. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• insulin lispro protamine/insulin lispro

  tolazamide, insulin lispro protamine/insulin lispro. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• insulin NPH

  tolazamide, insulin NPH. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• insulin regular human

  tolazamide, insulin regular human. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• isocarboxazid

  isocarboxazid increases effects of tolazamide by unknown mechanism. Use Caution/Monitor.

• ketoconazole

  ketoconazole increases levels of tolazamide by decreasing metabolism. Use Caution/Monitor.

• ketoprofen

  ketoprofen increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• ketorolac

  ketorolac increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• ketorolac intranasal

  ketorolac intranasal increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• ketotifen, ophthalmic

  ketotifen, ophthalmic, tolazamide. Other (see comment). Use Caution/Monitor. Comment: Combination may result in thrombocytopenia (rare). Monitor CBC.

• levofloxacin

  levofloxacin increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.

• linagliptin

  tolazamide, linagliptin. Other (see comment). Use Caution/Monitor. Comment: When linagliptin is used in combination with sulfonylureas, a lower dose of the sulfonylurea may be required to reduce risk of hypoglycemia.

• linezolid

  linezolid increases effects of tolazamide by unknown mechanism. Use Caution/Monitor.

• liraglutide

  liraglutide, tolazamide. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Serious hypoglycemia may occur when insulin secretagogues and GLP-1 agonists are concurrently administered. Consider lowering the dose of insulin secretagogue to reduce the risk of hypoglycemia. .

• lisinopril

  lisinopril increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor.

• lixisenatide

  lixisenatide, tolazamide. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Risk of hypoglycemia increased when coadministered with sulfonylureas. Sulfonylurea dosage reduction may be required.

• lopinavir

  lopinavir, tolazamide. Other (see comment). Use Caution/Monitor. Comment: Lopinavir may increase or decrease levels of tolazamide. Reports of hyperglycemia due to insulin resistance with protease inhibitors. .

• lornoxicam

  lornoxicam increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• lurasidone

  lurasidone, tolazamide. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

• marijuana

  marijuana decreases effects of tolazamide by pharmacodynamic antagonism. Use Caution/Monitor.

• mecasermin

  mecasermin increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects.

• meclofenamate

  meclofenamate increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• mefenamic acid

  mefenamic acid increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• meloxicam

  meloxicam increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• methyltestosterone

  methyltestosterone increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor. It is important to monitor all patients with type 2 diabetes on antidiabetic agents receiving androgens for changes in glycemic control. Potential for hypoglycemia.

• metreleptin

  tolazamide, metreleptin. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of metreleptin with insulin and/or insulin secretagogues (eg, sulfonylureas, meglitinide derivatives) may increase risk for hypoglycemia; may require lower dose of insulin or insulin secretagogue.

• miconazole vaginal

  miconazole vaginal increases levels of tolazamide by decreasing metabolism. Use Caution/Monitor.

• moexipril

  moexipril increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor.

• moxifloxacin

  moxifloxacin increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.

• nabumetone

  nabumetone increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• nadolol

  nadolol decreases effects of tolazamide by pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers may also mask the symptoms of hypoglycemia.

• naproxen

  naproxen increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• ofloxacin

  ofloxacin increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.

• olanzapine

  olanzapine, tolazamide. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

• opuntia ficus indica

  opuntia ficus indica increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor.

• oxaprozin

  oxaprozin increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• paliperidone

  paliperidone, tolazamide. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

• parecoxib

  parecoxib increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• perindopril

  perindopril increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor.

• phenelzine

  phenelzine increases effects of tolazamide by unknown mechanism. Use Caution/Monitor.

• pindolol

  pindolol decreases effects of tolazamide by pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers may also mask the symptoms of hypoglycemia.

• piroxicam

  piroxicam increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• posaconazole

  posaconazole increases levels of tolazamide by decreasing metabolism. Use Caution/Monitor.

• probenecid

  probenecid increases levels of tolazamide by unspecified interaction mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• propranolol

  propranolol decreases effects of tolazamide by pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers may also mask the symptoms of hypoglycemia.

• quetiapine

  quetiapine, tolazamide. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

• quinapril

  quinapril increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor.

• ramipril

  ramipril increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor.

• rifabutin

  rifabutin decreases levels of tolazamide by increasing metabolism. Use Caution/Monitor.

• rifampin

  rifampin decreases levels of tolazamide by increasing metabolism. Use Caution/Monitor.

• rifapentine

  rifapentine decreases levels of tolazamide by increasing metabolism. Use Caution/Monitor.

• risperidone

  risperidone, tolazamide. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

• ritonavir

  ritonavir, tolazamide. Other (see comment). Use Caution/Monitor. Comment: Ritonavir may increase or decrease levels of tolazamide. Reports of hyperglycemia due to insulin resistance with protease inhibitors. .

• salicylates (non-asa)

  salicylates (non-asa) increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• salsalate

  salsalate increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• selegiline

  selegiline increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Serum glucose should be monitored closely when MAOIs are added to any regimen containing antidiabetic medications. Hypoglycemic effects may be increased.

• selegiline transdermal

  selegiline transdermal increases effects of tolazamide by unknown mechanism. Use Caution/Monitor.

• semaglutide

  semaglutide, tolazamide. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin secretagogues with GLP-1 agonists may increase hypoglycemia risk. Lowering the insulin secretagogue dose may reduce hypoglycemia risk. .

• shark cartilage

  shark cartilage increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor. Theoretical interaction.

• somapacitan

  somapacitan decreases effects of tolazamide by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Growth hormone products may decrease insulin sensitivity, particularly at higher doses. Antidiabetic agents may require dose adjustment after initiating somapacitan. .

• sulfadiazine

  sulfadiazine increases levels of tolazamide by plasma protein binding competition. Use Caution/Monitor.

• sulfamethoxazole

  sulfamethoxazole increases levels of tolazamide by plasma protein binding competition. Use Caution/Monitor.

• sulfamethoxypyridazine

  sulfamethoxypyridazine increases effects of tolazamide by unspecified interaction mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• sulfasalazine

  sulfasalazine increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• sulfisoxazole

  sulfisoxazole increases levels of tolazamide by plasma protein binding competition. Use Caution/Monitor.

• sulindac

  sulindac increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• timolol

  timolol decreases effects of tolazamide by pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers may also mask the symptoms of hypoglycemia.

• tolfenamic acid

  tolfenamic acid increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• tolmetin

  tolmetin increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• trandolapril

  trandolapril increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor.

• tranylcypromine

  tranylcypromine increases effects of tolazamide by unknown mechanism. Use Caution/Monitor.

• triamcinolone acetonide injectable suspension

  triamcinolone acetonide injectable suspension decreases effects of tolazamide by pharmacodynamic antagonism. Use Caution/Monitor. Corticosteroids may diminish hypoglycemic effect of antidiabetic agents. Monitor blood glucose levels carefully.

• voriconazole

  voriconazole increases levels of tolazamide by decreasing metabolism. Use Caution/Monitor.

• xipamide

  xipamide decreases levels of tolazamide by increasing renal clearance. Use Caution/Monitor.

• ziprasidone

  ziprasidone, tolazamide. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

Minor (86)

• agrimony

  agrimony increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• American ginseng

  American ginseng increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• amitriptyline

  amitriptyline increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• amoxapine

  amoxapine increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• anamu

  anamu increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown. Theoretical interaction.

• aspirin

  aspirin increases effects of tolazamide by plasma protein binding competition. Minor/Significance Unknown. Large dose of salicylate.

• aspirin rectal

  aspirin rectal increases effects of tolazamide by plasma protein binding competition. Minor/Significance Unknown. Large dose of salicylate.

• aspirin/citric acid/sodium bicarbonate

  aspirin/citric acid/sodium bicarbonate increases effects of tolazamide by plasma protein binding competition. Minor/Significance Unknown. Large dose of salicylate.

• balsalazide

  balsalazide increases effects of tolazamide by plasma protein binding competition. Minor/Significance Unknown. Large dose of salicylate.

• bendroflumethiazide

  bendroflumethiazide decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

• budesonide

  budesonide decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown.

• chloramphenicol

  chloramphenicol increases levels of tolazamide by decreasing metabolism. Minor/Significance Unknown.

• chlorothiazide

  chlorothiazide decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

• chlorthalidone

  chlorthalidone decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

• choline magnesium trisalicylate

  choline magnesium trisalicylate increases effects of tolazamide by plasma protein binding competition. Minor/Significance Unknown. Large dose of salicylate.

• chromium

  chromium increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• clomipramine

  clomipramine increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• clonidine

  clonidine decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown. Diminished symptoms of hypoglycemia.
  
  clonidine, tolazamide. Other (see comment). Minor/Significance Unknown. Comment: Decreased symptoms of hypoglycemia. Mechanism: decreased hypoglycemia induced catecholamine production.

• coenzyme Q10

  tolazamide decreases levels of coenzyme Q10 by unspecified interaction mechanism. Minor/Significance Unknown.

• cornsilk

  cornsilk increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

• cortisone

  cortisone decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown.

• cyclopenthiazide

  cyclopenthiazide decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

• damiana

  damiana decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown. Theoretical interaction.

• danazol

  danazol increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• deflazacort

  deflazacort decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown.

• desipramine

  desipramine increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• devil's claw

  devil's claw increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• dexamethasone

  dexamethasone decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown.

• diflunisal

  diflunisal increases effects of tolazamide by plasma protein binding competition. Minor/Significance Unknown. Large dose of salicylate.

• doxepin

  doxepin increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• elderberry

  elderberry increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (in vitro research).

• ethotoin

  tolazamide increases levels of ethotoin by plasma protein binding competition. Minor/Significance Unknown.

• eucalyptus

  eucalyptus increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown. Theoretical interaction.

• fludrocortisone

  fludrocortisone decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown.

• fluoxymesterone

  fluoxymesterone increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• fo-ti

  fo-ti increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• forskolin

  forskolin increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown. Colenol, a compound found in Coleus root, may stimulate insulin release.

• fosphenytoin

  tolazamide increases levels of fosphenytoin by plasma protein binding competition. Minor/Significance Unknown.

• gotu kola

  gotu kola increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction).

• guanfacine

  guanfacine decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown. Diminished symptoms of hypoglycemia.
  
  guanfacine, tolazamide. Other (see comment). Minor/Significance Unknown. Comment: Decreased symptoms of hypoglycemia. Mechanism: decreased hypoglycemia induced catecholamine production.

• gymnema

  gymnema increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• horse chestnut seed

  horse chestnut seed increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• hydrochlorothiazide

  hydrochlorothiazide decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

• hydrocortisone

  hydrocortisone decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown.

• imipramine

  imipramine increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• indapamide

  indapamide decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

• isoniazid

  isoniazid decreases effects of tolazamide by unspecified interaction mechanism. Minor/Significance Unknown.

• juniper

  juniper increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

• lofepramine

  lofepramine increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• lycopus

  lycopus increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

• maitake

  maitake increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (animal research).

• maprotiline

  maprotiline increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• mesalamine

  mesalamine increases effects of tolazamide by plasma protein binding competition. Minor/Significance Unknown. Large dose of salicylate.

• mesterolone

  mesterolone increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• methyclothiazide

  methyclothiazide decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

• methylprednisolone

  methylprednisolone decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown.

• metolazone

  metolazone decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

• nettle

  nettle increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction).

• nortriptyline

  nortriptyline increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• ofloxacin

  ofloxacin, tolazamide. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential dysglycemia.

• orlistat

  orlistat increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• oxandrolone

  oxandrolone increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• oxymetholone

  oxymetholone increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• pegvisomant

  pegvisomant increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• phenytoin

  tolazamide increases levels of phenytoin by plasma protein binding competition. Minor/Significance Unknown.

• potassium acid phosphate

  potassium acid phosphate increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

• potassium chloride

  potassium chloride increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

• potassium citrate

  potassium citrate increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

• prednisolone

  prednisolone decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown.

• prednisone

  prednisone decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown.

• protriptyline

  protriptyline increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• sage

  sage increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• salicylates (non-asa)

  salicylates (non-asa) increases effects of tolazamide by plasma protein binding competition. Minor/Significance Unknown. Large dose of salicylate.

• salsalate

  salsalate increases effects of tolazamide by plasma protein binding competition. Minor/Significance Unknown. Large dose of salicylate.

• sitagliptin

  sitagliptin, tolazamide. Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypoglycemia with combination is unknown.

• stevia

  stevia increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• sulfasalazine

  sulfasalazine increases effects of tolazamide by plasma protein binding competition. Minor/Significance Unknown. Large dose of salicylate.

• tacrolimus

  tolazamide increases levels of tacrolimus by unknown mechanism. Minor/Significance Unknown.

• testosterone

  testosterone increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• testosterone buccal system

  testosterone buccal system increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• testosterone topical

  testosterone topical increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• tongkat ali

  tongkat ali increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypoglycemia.

• trazodone

  trazodone increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• trimipramine

  trimipramine increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• vanadium

  vanadium increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• willow bark

  willow bark increases effects of tolazamide by plasma protein binding competition. Minor/Significance Unknown. Large dose of salicylate.

• aceclofenac

  Monitor Closely (1)aceclofenac increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• acemetacin

  Monitor Closely (1)acemetacin increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• agrimony

  Minor (1)agrimony increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• albiglutide

  Monitor Closely (1)albiglutide, tolazamide. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Serious hypoglycemia may occur when insulin secretagogues and GLP-1 agonists are concurrently administered. Consider lowering the dose of insulin secretagogue to reduce the risk of hypoglycemia. .

• alogliptin

  Monitor Closely (1)alogliptin, tolazamide. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of alogliptin with insulin and/or insulin secretagogues (eg, sulfonylureas, meglitinide derivatives) may increase risk for hypoglycemia; may require lower dose of insulin or insulin secretagogue .

• American ginseng

  Minor (1)American ginseng increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• aminolevulinic acid oral

  Serious - Use Alternative (1)aminolevulinic acid oral, tolazamide. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid administering other phototoxic drugs with aminolevulinic acid oral for 24 hr during perioperative period.

• aminolevulinic acid topical

  Serious - Use Alternative (1)tolazamide increases toxicity of aminolevulinic acid topical by pharmacodynamic synergism. Avoid or Use Alternate Drug. Coadministration of photosensitizing drugs may enhance the phototoxic reaction to photodynamic therapy with aminolevulinic acid.

• amitriptyline

  Minor (1)amitriptyline increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• amoxapine

  Minor (1)amoxapine increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• anamu

  Minor (1)anamu increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown. Theoretical interaction.

• aripiprazole

  Monitor Closely (1)aripiprazole, tolazamide. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

• asenapine

  Monitor Closely (1)asenapine, tolazamide. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

• aspirin

  Monitor Closely (1)aspirin increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.Minor (1)aspirin increases effects of tolazamide by plasma protein binding competition. Minor/Significance Unknown. Large dose of salicylate.

• aspirin rectal

  Monitor Closely (1)aspirin rectal increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.Minor (1)aspirin rectal increases effects of tolazamide by plasma protein binding competition. Minor/Significance Unknown. Large dose of salicylate.

• aspirin/citric acid/sodium bicarbonate

  Monitor Closely (1)aspirin/citric acid/sodium bicarbonate increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.Minor (1)aspirin/citric acid/sodium bicarbonate increases effects of tolazamide by plasma protein binding competition. Minor/Significance Unknown. Large dose of salicylate.

• atazanavir

  Monitor Closely (1)atazanavir decreases effects of tolazamide by Other (see comment). Use Caution/Monitor. Comment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. .

• balsalazide

  Minor (1)balsalazide increases effects of tolazamide by plasma protein binding competition. Minor/Significance Unknown. Large dose of salicylate.

• benazepril

  Monitor Closely (1)benazepril increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor.

• bendroflumethiazide

  Minor (1)bendroflumethiazide decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

• bexarotene

  Monitor Closely (1)bexarotene increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor. Based on the mechanism of action, bexarotene capsules may increase the action of insulin enhancing agents, resulting in hypoglycemia. Hypoglycemia has not been associated with bexarotene monotherapy.

• bitter melon

  Monitor Closely (1)bitter melon increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypoglycemia.

• budesonide

  Minor (1)budesonide decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown.

• canagliflozin

  Monitor Closely (1)tolazamide, canagliflozin. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with canagliflozin.

• captopril

  Monitor Closely (1)captopril increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor.

• celecoxib

  Monitor Closely (1)celecoxib increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• chloramphenicol

  Minor (1)chloramphenicol increases levels of tolazamide by decreasing metabolism. Minor/Significance Unknown.

• chlorothiazide

  Minor (1)chlorothiazide decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

• chlorthalidone

  Minor (1)chlorthalidone decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

• choline magnesium trisalicylate

  Monitor Closely (1)choline magnesium trisalicylate increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.Minor (1)choline magnesium trisalicylate increases effects of tolazamide by plasma protein binding competition. Minor/Significance Unknown. Large dose of salicylate.

• chromium

  Minor (1)chromium increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• cinnamon

  Monitor Closely (1)cinnamon increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor. Potential for hypoglycemia.

• ciprofibrate

  Monitor Closely (1)ciprofibrate increases effects of tolazamide by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.

• ciprofloxacin

  Monitor Closely (1)ciprofloxacin increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor. Hyper and hypoglycemia have been reported in patients treated concomitantly with quinolones and antidiabetic agents. Careful monitoring of blood glucose is recommended.

• clarithromycin

  Monitor Closely (1)clarithromycin increases levels of tolazamide by plasma protein binding competition. Use Caution/Monitor. Risk of hypoglycemia.

• clomipramine

  Minor (1)clomipramine increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• clonidine

  Minor (2)clonidine decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown. Diminished symptoms of hypoglycemia.
  
  clonidine, tolazamide. Other (see comment). Minor/Significance Unknown. Comment: Decreased symptoms of hypoglycemia. Mechanism: decreased hypoglycemia induced catecholamine production.

• clotrimazole

  Monitor Closely (1)clotrimazole increases levels of tolazamide by decreasing metabolism. Use Caution/Monitor.

• clozapine

  Monitor Closely (1)clozapine, tolazamide. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

• coenzyme Q10

  Minor (1)tolazamide decreases levels of coenzyme Q10 by unspecified interaction mechanism. Minor/Significance Unknown.

• cornsilk

  Minor (1)cornsilk increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

• cortisone

  Minor (1)cortisone decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown.

• cyclopenthiazide

  Minor (1)cyclopenthiazide decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

• cyclosporine

  Monitor Closely (1)tolazamide, cyclosporine. unknown mechanism. Use Caution/Monitor. Cyclosporine may decrease the effects of sulfonylureas. Sulfonylureas may increase the effects of cyclosporine.

• damiana

  Minor (1)damiana decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown. Theoretical interaction.

• danazol

  Minor (1)danazol increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• dapagliflozin

  Monitor Closely (1)tolazamide, dapagliflozin. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with dapagliflozin.

• darunavir

  Monitor Closely (1)darunavir, tolazamide. Other (see comment). Use Caution/Monitor. Comment: Darunavir may increase or decrease levels of tolazamide. Use alternatives if available. Reports of hyperglycemia due to insulin resistance with protease inhibitors. .

• deflazacort

  Minor (1)deflazacort decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown.

• desipramine

  Minor (1)desipramine increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• devil's claw

  Minor (1)devil's claw increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• dexamethasone

  Minor (1)dexamethasone decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown.

• diclofenac

  Monitor Closely (1)diclofenac increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• diflunisal

  Monitor Closely (1)diflunisal increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.Minor (1)diflunisal increases effects of tolazamide by plasma protein binding competition. Minor/Significance Unknown. Large dose of salicylate.

• disopyramide

  Monitor Closely (1)disopyramide increases effects of tolazamide by unspecified interaction mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• doxepin

  Minor (1)doxepin increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• dulaglutide

  Monitor Closely (1)dulaglutide, tolazamide. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• elderberry

  Minor (1)elderberry increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (in vitro research).

• empagliflozin

  Monitor Closely (1)empagliflozin, tolazamide. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with SGLT2 inhibitors.

• enalapril

  Monitor Closely (1)enalapril increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor.

• ertugliflozin

  Monitor Closely (1)ertugliflozin, tolazamide. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Consider a lower dose of insulin or insulin secretagogue to avoid hypoglycemia when coadministered with ertugliflozin.

• ethanol

  Serious - Use Alternative (1)ethanol, tolazamide. Other (see comment). Contraindicated. Comment: Excessive EtOH consumption may alter glycemic control. Some sulfonylureas may produce a disulfiram like rxn.

• ethotoin

  Minor (1)tolazamide increases levels of ethotoin by plasma protein binding competition. Minor/Significance Unknown.

• etodolac

  Monitor Closely (1)etodolac increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• eucalyptus

  Minor (1)eucalyptus increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown. Theoretical interaction.

• exenatide injectable solution

  Monitor Closely (1)exenatide injectable solution, tolazamide. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of hypoglycemia when exenatide is used in combination with agents that induce hypoglycemia. Consider lowering dose of sulfonylureas to reduce risk of hypoglycemia. .

• exenatide injectable suspension

  Monitor Closely (1)exenatide injectable suspension, tolazamide. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of hypoglycemia when exenatide is used in combination with agents that induce hypoglycemia. Consider lowering dose of sulfonylureas to reduce risk of hypoglycemia.

• fenofibrate

  Monitor Closely (1)fenofibrate increases effects of tolazamide by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.

• fenofibrate micronized

  Monitor Closely (1)fenofibrate micronized increases effects of tolazamide by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.

• fenofibric acid

  Monitor Closely (1)fenofibric acid increases effects of tolazamide by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.

• fenoprofen

  Monitor Closely (1)fenoprofen increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• fleroxacin

  Monitor Closely (1)fleroxacin increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.

• fluconazole

  Monitor Closely (1)fluconazole increases levels of tolazamide by decreasing metabolism. Use Caution/Monitor.

• fludrocortisone

  Minor (1)fludrocortisone decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown.

• fluoxetine

  Monitor Closely (1)fluoxetine increases effects of tolazamide by unspecified interaction mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• fluoxymesterone

  Minor (1)fluoxymesterone increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• flurbiprofen

  Monitor Closely (1)flurbiprofen increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• fo-ti

  Minor (1)fo-ti increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• forskolin

  Minor (1)forskolin increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown. Colenol, a compound found in Coleus root, may stimulate insulin release.

• fosamprenavir

  Monitor Closely (1)fosamprenavir, tolazamide. Other (see comment). Use Caution/Monitor. Comment: Fosamprenavir may increase or decrease levels of tolazamide. Use alternatives if available. Reports of hyperglycemia due to insulin resistance with protease inhibitors. .

• fosinopril

  Monitor Closely (1)fosinopril increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor.

• fosphenytoin

  Minor (1)tolazamide increases levels of fosphenytoin by plasma protein binding competition. Minor/Significance Unknown.

• gemfibrozil

  Monitor Closely (1)gemfibrozil increases effects of tolazamide by plasma protein binding competition. Use Caution/Monitor. Hypoglycemia; increased risk in hypoalbuminemia.

• gemifloxacin

  Monitor Closely (1)gemifloxacin increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.

• gotu kola

  Minor (1)gotu kola increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction).

• guanfacine

  Minor (2)guanfacine decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown. Diminished symptoms of hypoglycemia.
  
  guanfacine, tolazamide. Other (see comment). Minor/Significance Unknown. Comment: Decreased symptoms of hypoglycemia. Mechanism: decreased hypoglycemia induced catecholamine production.

• gymnema

  Minor (1)gymnema increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• horse chestnut seed

  Minor (1)horse chestnut seed increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• hydrochlorothiazide

  Minor (1)hydrochlorothiazide decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

• hydrocortisone

  Minor (1)hydrocortisone decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown.

• ibuprofen

  Monitor Closely (1)ibuprofen increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• ibuprofen IV

  Monitor Closely (1)ibuprofen IV increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• iloperidone

  Monitor Closely (1)iloperidone, tolazamide. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

• imidapril

  Monitor Closely (1)imidapril increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor.

• imipramine

  Minor (1)imipramine increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• indapamide

  Minor (1)indapamide decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

• indomethacin

  Monitor Closely (1)indomethacin increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• insulin aspart

  Monitor Closely (1)tolazamide, insulin aspart. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• insulin aspart protamine/insulin aspart

  Monitor Closely (1)tolazamide, insulin aspart protamine/insulin aspart. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• insulin degludec

  Monitor Closely (1)tolazamide, insulin degludec. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• insulin degludec/insulin aspart

  Monitor Closely (1)tolazamide, insulin degludec/insulin aspart. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• insulin detemir

  Monitor Closely (1)tolazamide, insulin detemir. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• insulin glargine

  Monitor Closely (1)tolazamide, insulin glargine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• insulin glulisine

  Monitor Closely (1)tolazamide, insulin glulisine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• insulin inhaled

  Monitor Closely (1)tolazamide, insulin inhaled. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• insulin isophane human/insulin regular human

  Monitor Closely (1)tolazamide, insulin isophane human/insulin regular human. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• insulin lispro

  Monitor Closely (1)tolazamide, insulin lispro. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• insulin lispro protamine/insulin lispro

  Monitor Closely (1)tolazamide, insulin lispro protamine/insulin lispro. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• insulin NPH

  Monitor Closely (1)tolazamide, insulin NPH. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• insulin regular human

  Monitor Closely (1)tolazamide, insulin regular human. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Antidiabetic agents are often used in combination; dosage adjustments may be required when initiating or discontinuing antidiabetic agents.

• isocarboxazid

  Monitor Closely (1)isocarboxazid increases effects of tolazamide by unknown mechanism. Use Caution/Monitor.

• isoniazid

  Minor (1)isoniazid decreases effects of tolazamide by unspecified interaction mechanism. Minor/Significance Unknown.

• juniper

  Minor (1)juniper increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

• ketoconazole

  Monitor Closely (1)ketoconazole increases levels of tolazamide by decreasing metabolism. Use Caution/Monitor.

• ketoprofen

  Monitor Closely (1)ketoprofen increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• ketorolac

  Monitor Closely (1)ketorolac increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• ketorolac intranasal

  Monitor Closely (1)ketorolac intranasal increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• ketotifen, ophthalmic

  Monitor Closely (1)ketotifen, ophthalmic, tolazamide. Other (see comment). Use Caution/Monitor. Comment: Combination may result in thrombocytopenia (rare). Monitor CBC.

• levofloxacin

  Monitor Closely (1)levofloxacin increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.

• linagliptin

  Monitor Closely (1)tolazamide, linagliptin. Other (see comment). Use Caution/Monitor. Comment: When linagliptin is used in combination with sulfonylureas, a lower dose of the sulfonylurea may be required to reduce risk of hypoglycemia.

• linezolid

  Monitor Closely (1)linezolid increases effects of tolazamide by unknown mechanism. Use Caution/Monitor.

• liraglutide

  Monitor Closely (1)liraglutide, tolazamide. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Serious hypoglycemia may occur when insulin secretagogues and GLP-1 agonists are concurrently administered. Consider lowering the dose of insulin secretagogue to reduce the risk of hypoglycemia. .

• lisinopril

  Monitor Closely (1)lisinopril increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor.

• lixisenatide

  Monitor Closely (1)lixisenatide, tolazamide. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Risk of hypoglycemia increased when coadministered with sulfonylureas. Sulfonylurea dosage reduction may be required.

• lofepramine

  Minor (1)lofepramine increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• lopinavir

  Monitor Closely (1)lopinavir, tolazamide. Other (see comment). Use Caution/Monitor. Comment: Lopinavir may increase or decrease levels of tolazamide. Reports of hyperglycemia due to insulin resistance with protease inhibitors. .

• lornoxicam

  Monitor Closely (1)lornoxicam increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• lumacaftor/ivacaftor

  Serious - Use Alternative (1)lumacaftor/ivacaftor will decrease the level or effect of tolazamide by affecting hepatic enzyme CYP2C9/10 metabolism. Avoid or Use Alternate Drug. Sulfonylureas are CYP2C9 substrates. Lumacaftor/ivacaftor has the potential to induce CYP2C9.

• lurasidone

  Monitor Closely (1)lurasidone, tolazamide. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

• lycopus

  Minor (1)lycopus increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (theoretical interaction).

• maitake

  Minor (1)maitake increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of hypoglycemia (animal research).

• maprotiline

  Minor (1)maprotiline increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• marijuana

  Monitor Closely (1)marijuana decreases effects of tolazamide by pharmacodynamic antagonism. Use Caution/Monitor.

• mecasermin

  Monitor Closely (1)mecasermin increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor. Additive hypoglycemic effects.

• meclofenamate

  Monitor Closely (1)meclofenamate increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• mefenamic acid

  Monitor Closely (1)mefenamic acid increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• meloxicam

  Monitor Closely (1)meloxicam increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• mesalamine

  Minor (1)mesalamine increases effects of tolazamide by plasma protein binding competition. Minor/Significance Unknown. Large dose of salicylate.

• mesterolone

  Minor (1)mesterolone increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• methyclothiazide

  Minor (1)methyclothiazide decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

• methyl aminolevulinate

  Serious - Use Alternative (1)tolazamide, methyl aminolevulinate. Either increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Each drug may increase the photosensitizing effect of the other.

• methylprednisolone

  Minor (1)methylprednisolone decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown.

• methyltestosterone

  Monitor Closely (1)methyltestosterone increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor. It is important to monitor all patients with type 2 diabetes on antidiabetic agents receiving androgens for changes in glycemic control. Potential for hypoglycemia.

• metolazone

  Minor (1)metolazone decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown. Thiazide dosage >50 mg/day may increase blood glucose.

• metreleptin

  Monitor Closely (1)tolazamide, metreleptin. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of metreleptin with insulin and/or insulin secretagogues (eg, sulfonylureas, meglitinide derivatives) may increase risk for hypoglycemia; may require lower dose of insulin or insulin secretagogue.

• miconazole vaginal

  Monitor Closely (1)miconazole vaginal increases levels of tolazamide by decreasing metabolism. Use Caution/Monitor.

• moexipril

  Monitor Closely (1)moexipril increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor.

• moxifloxacin

  Monitor Closely (1)moxifloxacin increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.

• nabumetone

  Monitor Closely (1)nabumetone increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• nadolol

  Monitor Closely (1)nadolol decreases effects of tolazamide by pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers may also mask the symptoms of hypoglycemia.

• naproxen

  Monitor Closely (1)naproxen increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• nettle

  Minor (1)nettle increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown. (Theoretical interaction).

• nortriptyline

  Minor (1)nortriptyline increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• ofloxacin

  Monitor Closely (1)ofloxacin increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor. Quinolone antibiotic administration may result in hyper- or hypoglycemia. Gatifloxacin is most likely to produce dysglycemia; moxifloxacin is least likely.Minor (1)ofloxacin, tolazamide. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Potential dysglycemia.

• olanzapine

  Monitor Closely (1)olanzapine, tolazamide. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

• opuntia ficus indica

  Monitor Closely (1)opuntia ficus indica increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor.

• orlistat

  Minor (1)orlistat increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• oxandrolone

  Minor (1)oxandrolone increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• oxaprozin

  Monitor Closely (1)oxaprozin increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• oxymetholone

  Minor (1)oxymetholone increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• paliperidone

  Monitor Closely (1)paliperidone, tolazamide. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

• parecoxib

  Monitor Closely (1)parecoxib increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• pegvisomant

  Minor (1)pegvisomant increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• perindopril

  Monitor Closely (1)perindopril increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor.

• phenelzine

  Monitor Closely (1)phenelzine increases effects of tolazamide by unknown mechanism. Use Caution/Monitor.

• phenytoin

  Minor (1)tolazamide increases levels of phenytoin by plasma protein binding competition. Minor/Significance Unknown.

• pindolol

  Monitor Closely (1)pindolol decreases effects of tolazamide by pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers may also mask the symptoms of hypoglycemia.

• piroxicam

  Monitor Closely (1)piroxicam increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• posaconazole

  Monitor Closely (1)posaconazole increases levels of tolazamide by decreasing metabolism. Use Caution/Monitor.

• potassium acid phosphate

  Minor (1)potassium acid phosphate increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

• potassium chloride

  Minor (1)potassium chloride increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

• potassium citrate

  Minor (1)potassium citrate increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown. Interaction especially seen in the treatment of hypokalemia.

• prednisolone

  Minor (1)prednisolone decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown.

• prednisone

  Minor (1)prednisone decreases effects of tolazamide by pharmacodynamic antagonism. Minor/Significance Unknown.

• probenecid

  Monitor Closely (1)probenecid increases levels of tolazamide by unspecified interaction mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• propranolol

  Monitor Closely (1)propranolol decreases effects of tolazamide by pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers may also mask the symptoms of hypoglycemia.

• protriptyline

  Minor (1)protriptyline increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• quetiapine

  Monitor Closely (1)quetiapine, tolazamide. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

• quinapril

  Monitor Closely (1)quinapril increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor.

• ramipril

  Monitor Closely (1)ramipril increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor.

• rifabutin

  Monitor Closely (1)rifabutin decreases levels of tolazamide by increasing metabolism. Use Caution/Monitor.

• rifampin

  Monitor Closely (1)rifampin decreases levels of tolazamide by increasing metabolism. Use Caution/Monitor.

• rifapentine

  Monitor Closely (1)rifapentine decreases levels of tolazamide by increasing metabolism. Use Caution/Monitor.

• risperidone

  Monitor Closely (1)risperidone, tolazamide. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.

• ritonavir

  Monitor Closely (1)ritonavir, tolazamide. Other (see comment). Use Caution/Monitor. Comment: Ritonavir may increase or decrease levels of tolazamide. Reports of hyperglycemia due to insulin resistance with protease inhibitors. .

• sage

  Minor (1)sage increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• salicylates (non-asa)

  Monitor Closely (1)salicylates (non-asa) increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.Minor (1)salicylates (non-asa) increases effects of tolazamide by plasma protein binding competition. Minor/Significance Unknown. Large dose of salicylate.

• salsalate

  Monitor Closely (1)salsalate increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.Minor (1)salsalate increases effects of tolazamide by plasma protein binding competition. Minor/Significance Unknown. Large dose of salicylate.

• selegiline

  Monitor Closely (1)selegiline increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Serum glucose should be monitored closely when MAOIs are added to any regimen containing antidiabetic medications. Hypoglycemic effects may be increased.

• selegiline transdermal

  Monitor Closely (1)selegiline transdermal increases effects of tolazamide by unknown mechanism. Use Caution/Monitor.

• semaglutide

  Monitor Closely (1)semaglutide, tolazamide. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of insulin secretagogues with GLP-1 agonists may increase hypoglycemia risk. Lowering the insulin secretagogue dose may reduce hypoglycemia risk. .

• shark cartilage

  Monitor Closely (1)shark cartilage increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor. Theoretical interaction.

• sitagliptin

  Minor (1)sitagliptin, tolazamide. Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypoglycemia with combination is unknown.

• somapacitan

  Monitor Closely (1)somapacitan decreases effects of tolazamide by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Growth hormone products may decrease insulin sensitivity, particularly at higher doses. Antidiabetic agents may require dose adjustment after initiating somapacitan. .

• stevia

  Minor (1)stevia increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• sulfadiazine

  Monitor Closely (1)sulfadiazine increases levels of tolazamide by plasma protein binding competition. Use Caution/Monitor.

• sulfamethoxazole

  Monitor Closely (1)sulfamethoxazole increases levels of tolazamide by plasma protein binding competition. Use Caution/Monitor.

• sulfamethoxypyridazine

  Monitor Closely (1)sulfamethoxypyridazine increases effects of tolazamide by unspecified interaction mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• sulfasalazine

  Monitor Closely (1)sulfasalazine increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.Minor (1)sulfasalazine increases effects of tolazamide by plasma protein binding competition. Minor/Significance Unknown. Large dose of salicylate.

• sulfisoxazole

  Monitor Closely (1)sulfisoxazole increases levels of tolazamide by plasma protein binding competition. Use Caution/Monitor.

• sulindac

  Monitor Closely (1)sulindac increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• tacrolimus

  Minor (1)tolazamide increases levels of tacrolimus by unknown mechanism. Minor/Significance Unknown.

• testosterone

  Minor (1)testosterone increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• testosterone buccal system

  Minor (1)testosterone buccal system increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• testosterone topical

  Minor (1)testosterone topical increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• timolol

  Monitor Closely (1)timolol decreases effects of tolazamide by pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers may also mask the symptoms of hypoglycemia.

• tolfenamic acid

  Monitor Closely (1)tolfenamic acid increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• tolmetin

  Monitor Closely (1)tolmetin increases effects of tolazamide by unknown mechanism. Use Caution/Monitor. Risk of hypoglycemia.

• tongkat ali

  Minor (1)tongkat ali increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypoglycemia.

• trandolapril

  Monitor Closely (1)trandolapril increases effects of tolazamide by pharmacodynamic synergism. Use Caution/Monitor.

• tranylcypromine

  Monitor Closely (1)tranylcypromine increases effects of tolazamide by unknown mechanism. Use Caution/Monitor.

• trazodone

  Minor (1)trazodone increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• triamcinolone acetonide injectable suspension

  Monitor Closely (1)triamcinolone acetonide injectable suspension decreases effects of tolazamide by pharmacodynamic antagonism. Use Caution/Monitor. Corticosteroids may diminish hypoglycemic effect of antidiabetic agents. Monitor blood glucose levels carefully.

• trimipramine

  Minor (1)trimipramine increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• vanadium

  Minor (1)vanadium increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

• voriconazole

  Monitor Closely (1)voriconazole increases levels of tolazamide by decreasing metabolism. Use Caution/Monitor.

• willow bark

  Minor (1)willow bark increases effects of tolazamide by plasma protein binding competition. Minor/Significance Unknown. Large dose of salicylate.

• xipamide

  Monitor Closely (1)xipamide decreases levels of tolazamide by increasing renal clearance. Use Caution/Monitor.

• ziprasidone

  Monitor Closely (1)ziprasidone, tolazamide. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.